Five-year relapse-free survival was higher in acute myeloid leukemia (AML) patients aged ≥60 years who underwent reduced-intensity allogeneic transplantation in first remission than in patients who did not undergo transplant, according to research results presented at the 2014 ASH Annual Meeting. In this multi-center study, 640 patients with newly diagnosed AML were studied, with a median age of 66 years (range 60-82). Five-year relapse-free survival (RFS) was significantly higher in patients who underwent reduced-intensity HCT compared to patients who received chemotherapy or no further treatment: 32% vs.17%, respectively (p=0.02). The study also demonstrated that 5-year OS was significantly improved in patients with intermediate and poor-risk AML receiving an allogeneic HCT compared to favorable risk and non-transplanted patients: 34% vs. 8%, respectively; p=0.002.
Reduced-Intensity HCT Significantly Improves Survival in Elderly Patients with AML in CR1